Brought to you by 
AbbVie shells out $5.8bn in cash and stock for cancer firm Stemcentrx
25 Aug 2020
Executive Summary
Continuing to build its oncology pipeline, AbbVie Inc. is paying $5.8bn--$2bn in cash and $3.8bn in stock--to acquire private cancer-focused firm Stemcentrx Inc. AbbVie could also shell out up to $4bn in cash related to clinical development and regulatory earn-outs.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Payment Includes Cash
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AbbVie shells out $5.8bn in cash and stock for cancer firm Stemcentrx
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice